Table 1.
No. of ceftazidime resistant isolates | ESBL Positive (%) | AmpC Positive (%) | MBL Positive (%) | |
---|---|---|---|---|
In-patients | 51 | 11 (21.6) | 6 (11.8) | 38 (74.5) |
Out-patients | 16 | 2 (12.5) | 5 (31.3) | 6 (37.5) |
Total | 67 | 13 (19.4) | 11 (16.4) | 44 (65.7) |
ESBL – Extended spectrum β-lactamase
MBL – Metallo-β-lactamase
AmpC – AmpC β-lactamase